ONWARD Medical successfully raised an amount of EUR 40.6M in gross proceeds by way of an accelerated bookbuild offering through a private placement with institutional investors. The successful transaction includes an EUR 25.0M investment by EQT Life Sciences. ONWARD’s cash runway now extends into Q1 2028..

ONWARD Medical通过向机构投资者私募的方式，以加速建档发行成功筹集了4060万欧元的毛收入。这笔成功交易包括EQT生命科学公司投资的2500万欧元。ONWARD的现金跑道现已延长至2028年第一季度。

ONWARD Medical

向前医疗

is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. The Company’s ARC-EX System is cleared for commercial sale in the US and Europe. The Company is also developing an investigational implantable system called ARC-IM, designed to address several unmet needs including blood pressure instability after spinal cord injury.

是领先的神经技术公司，率先开发出恢复脊髓损伤（SCI）患者及其他运动障碍患者的运动、功能和独立性的疗法。该公司的ARC-EX系统已获准在美国和欧洲进行商业销售。该公司还正在开发一种名为ARC-IM的可植入研究系统，旨在解决多种未满足的需求，包括脊髓损伤后的血压不稳定问题。

It can also be paired with a brain-computer interface (BCI) and artificial intelligence (AI) to restore thought-driven movement..

它还可以与脑机接口 (BCI) 和人工智能 (AI) 配对，以恢复由思想驱动的运动。

ONWARD currently envisions using the net proceeds of the Private Placement, together with the existing cash balance, to:

ONWARD 目前计划将此次私募配售的净收益与现有现金余额一起用于：

Fund development initiatives, including but not limited to product development, clinical studies and regulatory activities for the investigational ARC-IM System to address blood pressure instability in people with spinal cord injury (40%);

为解决脊髓损伤患者血压不稳定问题的ARC-IM系统开发项目提供资金支持，包括但不限于产品开发、临床研究和监管活动（40%）；

Expand sales efforts and related operations to support commercialization of the ARC-EX System in the US, Europe and select other geographies (30%);

拓展销售工作及相关运营，以支持ARC-EX系统在美国、欧洲及选定其他地区的商业化（30%）；

Support and scale quality and administrative activities (20%); and

支持和扩展质量和行政活动（20%）；以及

Support working capital, general corporate purposes, and the servicing of existing debt obligations (10%).

支持营运资金、一般企业用途以及现有债务义务的服务（10%）。

Dave Marver, CEO of ONWARD Medical, said: “The strong support from EQT and other high-quality investors underscores the rapid adoption of the ARC-EX System and validates our successful transition to a commercial-stage organization. It also affirms the potential of ARC-IM, our groundbreaking implantable technology platform that is currently under clinical evaluation in the Empower BP pivotal trial.”.

ONWARD Medical首席执行官戴夫·马弗表示：“EQT和其他高质量投资者的大力支持，表明ARC-EX系统的快速应用，并验证了我们成功转型为商业阶段的组织。这也肯定了我们目前正在进行Empower BP关键试验临床评估的突破性植入技术平台ARC-IM的潜力。”

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送